

Title	The SENATOR project: developing and trialling a novel software engine to optimize medications and nonpharmacological therapy in older people with multimorbidity and polypharmacy
Authors	Soiza, Roy L.;Subbarayan, Selvarani;Antonio, Cherubini;Cruz-Jentoft, Alfonso;Petrovic, Mirko;Gudmundsson, Adalsteinn;O'Mahony, Denis
Publication date	2017
Original Citation	Soiza, R. L., Subbarayan, S., Antonio, C., Cruz-Jentoft, A. J., Petrovic, M., Gudmundsson, A. and O'Mahony, D. (2016) 'The SENATOR project: developing and trialling a novel software engine to optimize medications and nonpharmacological therapy in older people with multimorbidity and polypharmacy', Therapeutic Advances in Drug Safety, 8(3), pp. 81-85. doi: 10.1177/2042098616675851
Type of publication	Other
Link to publisher's version	<a href="http://journals.sagepub.com/doi/full/10.1177/2042098616675851">http://journals.sagepub.com/doi/full/10.1177/2042098616675851</a> - 10.1177/2042098616675851
Rights	© 2016, the Authors. This manuscript version is reprinted by permission of SAGE Publications. - <a href="http://www.sagepub.co.uk/journalsPermissions.nav">http://www.sagepub.co.uk/journalsPermissions.nav</a>
Download date	2024-09-21 19:15:12
Item downloaded from	<a href="https://hdl.handle.net/10468/6521">https://hdl.handle.net/10468/6521</a>



# UCC

**University College Cork, Ireland**  
Coláiste na hOllscoile Corcaigh

The SENATOR project: developing and trialling a novel software engine to optimise medications and non-pharmacological therapy in older people with multimorbidity and polypharmacy

Soiza RL, Subbarayan S, Cherubini A, Cruz-Jentoft AJ, Petrovic M, Gudmonsson A, O'Mahony D.

**Author list:**

Roy L Soiza, Dept of Medicine for the Elderly, NHS Grampian, Aberdeen, UK; roy.soiza@nhs.net\*

Selvarani Subbarayan, AGEING Research Group, University of Aberdeen, Aberdeen, UK;  
selvarani.subbarayan@abdn.ac.uk

Antonio Cherubini, Italian National Research Centre on Aging, (IRCCS-INRCA), Ancona, Italy;  
a.cherubini@inrca.it

Alfonso J Cruz-Jentoft, Servicio de Geriátría, Hospital Universitario Ramón y Cajal, Madrid, Spain;  
alfonsojose.cruz@salud.madrid.org

Mirko Petrovic, Ghent University Hospital, Ghent, Belgium; mirko.petrovic@ugent.be

Adalsteinn Gudmondsson, Landspítali University Hospital, Reykjavik, Iceland; adalstg@landspitali.is

Denis O'Mahony, University College Cork, Ireland; denis.omahony@ucc.ie

\* Corresponding author

## **Abstract**

Optimisation of drug and non-drug therapy in older people with multiple co-morbidities is a frequently encountered and highly challenging problem in most fields of medicine. The relative undersupply of clinicians with special interest and expertise in this area means most clinicians may need better guidance or tools to aid management. However, the utility of guidelines and existing tools is limited by the complexity and heterogeneity of this patient population. The SENATOR consortium ambitiously set out to develop and test a novel software engine that would give non-expert clinicians bespoke recommendations on evidence-based pharmacological and non-pharmacological therapy, based on each patient's unique characteristics. The SENATOR software incorporates validated tools, such as the START/STOPP criteria, but is also developing new tools such as the Optimisation of Non-drug Therapy in Older People (ONTOP) for its inclusion. Here, we briefly describe the aims, first steps, challenges and progress so far in the development and testing of the SENATOR software.

## Introduction

Older people have the highest prevalence rates of polypharmacy, inappropriate prescribing and adverse drug reactions (ADRs) with associated high levels of morbidity [Permpongkosol 2011; Scott & Jayathissa 2010]. Studies from several European countries consistently show about 6% of all hospital admissions in adults can be directly attributed to ADRs [Pirmohamed 2004; Franceschi et al 2008; Hamilton et al 2011]. Another large study in the Netherlands calculated that €94M (0.5%) of the country's total hospital budget was spent on medication-related admissions [Leendertse et al 2011]. The cost for the UK was estimated around €706M in 2004 [Pirmohamed et al] and €434M in Germany in 2006 [Rottenkolber et al 2011]. There is wide agreement that the best strategy to prevent ADR-related morbidity is to focus on high-risk groups such as older people with polypharmacy [Leendertse et al 2011; Dequito et al 2011]. Demand for geriatricians and other specialists in this field far outweigh supply, so the prospect of easy-to-use software to guide clinicians has tremendous potential to improve patient care. However, a major challenge is that any software solutions would need to safely handle the complexity that characterises this patient group. A recent review concluded that there are no validated, reliable, widely-used prevention strategies in older people [Petrovic et al 2012]. Although there are a number of well known existing tools such as the STOPP-START criteria [O'Mahony et al 2015] and Beers criteria [AGS Beers Criteria Update Expert Panel, 2015], they are usually limited to use in research and are not easily applied in routine clinical practice due to the volume of information and multiple rules that apply [Caslake et al 2013]. Some interventions provide a structured format for the review of prescribed medication, but either rely on the clinician's considerable specialist clinical pharmacology knowledge in older people or involve applying one of the above tools (e.g. the systematic tool to reduce inappropriate prescribing (STRIP)) [Keijsers et al 2015]. A number of Computerised Provider Order Entry (CPOE) systems are in use for electronic prescribing, but none are specially designed for older people and, though partly effective, they rely mostly on warning clinicians only about drug-drug interactions [Schiff et al 2015]. Moreover, another potentially important strategy to avoid ADRs involves maximising use of

evidence-based non-pharmacological therapies but none of the above tools address this. Therefore, there was a clear need to develop and validate a new and more sophisticated tool that could address this important gap. Here, we describe the efforts made to date by our group to develop and test a new software engine for the optimisation of medical and non-drug therapy in older people with multi-morbidity and polypharmacy (SENATOR).

### **Establishing the SENATOR consortium**

The SENATOR consortium is an international collaboration funded under the European Union FP7 programme ([www.senator-project.eu](http://www.senator-project.eu)). This followed a call for investigator-driven projects to address management of elderly individuals with multiple diseases. It is led by Prof Denis O'Mahony in University College Cork and includes collaborators from 12 European organisations with a wide range of expertise including geriatric medicine, clinical pharmacology, software design and project management.

### **SENATOR software**

The SENATOR software incorporates a number of individually validated tools to provide clinicians with evidence-based recommendations. Key components include the START-STOPP2 criteria [O'Mahony et al 2015] and databases of licensed indications for medications and drug-drug interactions (from the British National Formulary and a licensed CPOE product called SafeScript). The risk of death in the next year is calculated using CIRS-G (Cumulative Illness Rating Scale for Geriatrics) [Miller et al 1992]. Another novel component is a tool that predicts the risk of an ADR, since this may influence the extent of de-prescribing. Since the best current tools, such as GerontoNet [Onder et al 2010], have only moderate ability to predict ADRs in older people [Petrovic et al 2012], the study team plan to create, test and validate its own bespoke tool from the extensive

clinical data that was being collected for the study. This will only be incorporated into the final product if it is superior to GerontoNet when validated. Provided the software is given enough information on the patient's medical history and usual medications, it can make recommendations on inappropriate prescribing. This includes addressing under-prescribing of evidence-based treatments and recommendations for medication withdrawal to combat polypharmacy. To help keep prescribing costs down, SENATOR has information on drug availability, pricing and policies for each participating centre, and can make recommendations on the most cost effective option. The latter involved a significant amount of original development work as this information is not easily available. The SENATOR software's output is in the form of easy to follow bullet-point recommendations. They will still require clinicians to make their own, final judgment in conjunction with the patient themselves, as there are a number of factors that the software cannot easily take into account. In particular, there is no way of taking into account patient preference, or the result of any previous attempts at medical optimisation.

### **Non-drug therapies**

One of the most exciting and innovative aspects of the SENATOR project is the development of individually tailored advice on appropriate non-pharmacological therapies. This aspect has required considerable original research and development as there are no existing compendia of non-pharmacological therapies, along with their evidence-based indications. This is in stark contrast to pharmacological therapies, where regularly updated tomes, such as the British National Formulary, provide clinicians with all the information they need for safe prescribing in an easily accessible format. It is therefore perhaps unsurprising that non-drug therapies are currently under-utilised [Chen et al, 2014; Naci and Ionnadis, 2013].

The SENATOR project developed a bespoke methodology to gather the best available evidence called ONTOP (Optimal Non-drug Therapy for Older Persons) [for a detailed description see Abraha et al 2015]. Initially, common geriatric conditions that may respond to non-drug therapy were selected for inclusion by panel discussion involving all the principal SENATOR investigators (authors). For each one, an international panel of 13 experts were asked to list and rate the clinical importance of all available outcome measures with the aim of identifying critically important outcome measures using a Delphi technique. For example, for the management of pressure ulcers, rates of complete wound healing was rated as a critically important outcome measure, whereas length of hospital stay was not. The next stage involved a 'systematic review of systematic reviews' of each condition, without specifying any individual interventions. This was important to avoid missing any little-known interventions. Reports were included if they assessed any non-drug therapy using systematic review methodology. From included reviews, all relevant primary studies were identified for inclusion in the final analysis. Usual inclusion criteria included: mean study population age over 65 years, randomised controlled trial design and outcomes measures that included at least one rated as critically important by the Delphi panel. This allowed the team to generate specific questions using PICO (Population, Intervention, Comparator, Outcomes) methodology to evaluate the evidence-base of each intervention for each condition, and in specific patient groups. Meta-analyses were used where appropriate. Finally, results of each meta-analysis and systematic review are evaluated for quality using the GRADE methodology [Guyatt et al, 2011]. Bullet-form recommendations for inclusion in the SENATOR software are written where there is at least moderate evidence of effect. These recommendations can potentially be individualised for patients by the software (e.g. a recommendation for group exercise therapy may only be triggered where incontinence is listed as a problem, and the patient is female).

The initial SENATOR trial includes a 'proof of concept' study testing the feasibility of making computer-generated recommendations on non-pharmacological therapy. Initially, the trial will evaluate whether clinical teams follow advice on the prevention of delirium using non-drug

techniques. The final SENATOR software will include recommendations on the non-drug treatment and/or prevention of ten common geriatric conditions and some of the ONTOP reviews are already available (see Table 1) [Abraha et al, 2015; Abraha et al, 2016; Lozano-Montoya et al 2016; Vélez-Díaz-Pallarés et al 2015; Vélez-Díaz-Pallarés et al 2016, Rimland et al 2016].

### **Pan-European tool**

One of the remits of the project was that any tool that was developed would be suitable for use throughout Europe. This represents a major challenge, as healthcare systems, therapy availability and practices vary widely. Moreover, there are significant language barriers. A major work package was devised to translate and reverse-translate all the SENATOR user interfaces and recommendations from English to Spanish, French, Italian and Icelandic to cover the native language of all the countries that would test the software in a clinical trial.

### **Testing the software**

One of the major goals of SENATOR is to reduce ADR, so the rate of ADR was the obvious primary outcome for a randomised controlled trial. Although SENATOR is designed to be used in any setting, a decision was made to test it in the hospitalised setting first as this allowed more pragmatic recruitment of large numbers of volunteers at high risk of ADR within a short time period. Trials of interventions to reduce ADR pose several challenges. It is impossible to achieve effective and safe blinding of clinicians and patients. There is a risk of contamination of the control group due to clinicians learning from the intervention. Although these risks can be mitigated with a cluster-randomised design, the latter also poses many challenges. The underlying risk of ADR in different ward areas varies widely, so many different clusters would be needed to avoid an inherent bias in one arm just by chance. Moreover, out of hours cross-cover arrangements and the high workplace



mobility of trainee medical staff between control and intervention units would mean the risk of contamination across clusters remained. Additionally, the danger of ascertainment bias is high as ADRs in older people can easily be missed or dismissed.

In an attempt to overcome many of these inherent difficulties, the SENATOR trial was divided into two distinct trial periods. The first was an observational study across hospitals in six different countries. This allowed verification of recruitment rate and baseline ADR rate across each country and within each region in different types of wards. It also allowed the development and testing of the SENATOR software interface, a tool to predict ADR and the feasibility of data collection for all the SENATOR components ahead of the trial in Period 2. The randomised controlled trial (Period 2) will start in 2016 and will be an unblinded controlled trial with randomisation at the level of the patient. Important secondary outcome measures include quality of life, length of stay in hospital, mortality, and healthcare utilisation costs both during the admission and at 3 months follow-up.

## **Dissemination**

The trial protocol is publicly available (<https://clinicaltrials.gov/ct2/show/NCT02097654>) and all major findings will be presented widely at international conferences and published in major scientific journals. Results of the main trial should become available late in 2018. If successful, SENATOR will be an extremely useful adjunct to any clinician working with older people.

## References

- Abraha, I., Cruz-Jentoft, A., Soiza, R.L., O'Mahony, D., Cherubini, A. (2015) Evidence of and recommendations for non-pharmacological interventions for common geriatric conditions: the SENATOR-ONTOP systematic review protocol. *BMJ Open* 5:e007488
- Abraha, I., Trotta, F., Rimland, J.M., Cruz-Jentoft, A., Lozano-Montoya, I., Soiza, R.L., et al. (2015) Efficacy of Non-Pharmacological Interventions to Prevent and Treat Delirium in Older Patients: A Systematic Overview. The SENATOR project ONTOP Series. *PLoS ONE* 10:e0123090
- Abraha, I., Mirella, F., Rimland, J.M., Cruz-Jentoft, A., Lozano-Montoya, I., Soiza, R.L., et al. (2016) Non-pharmacological interventions to prevent or treat delirium in older patients: Clinical practice recommendations. *J Nutr Health Aging* (in press)
- American Geriatrics Society 2015 Beers Criteria Update Expert Panel. (2015) American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc* 63:2227-2246
- Caslake, R., Soiza, R.L., Mangoni, A.A. (2013) Practical advice for prescribing in old age. *Medicine* 41:9-12
- Chen, R.C., Liu, C.L., Lin, M.H., Peng, L.N., Chen, L.Y., Liu, L.K., et al. (2014) Non-pharmacological treatment reducing not only behavioral symptoms, but also psychotic symptoms of older adults with dementia: a prospective cohort study in Taiwan. *Geriatr Gerontol Int* 14:440-446
- Dequito, A.B., Mol, P.G., van Doormaal, J.E., Zaal, R.J., van den Bemt, P.M., Haaijer-Ruskamp, F.M., et al. (2011) Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands. *Drug Saf* 34:1089-1100

Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, et al. (2008) Prevalence, clinical features and avoidability of diverse drug reactions as cause of admission to a geriatric unit. A prospective study of 1756 patients. *Drug Safety* 3:545-56

Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., Brozek, J., et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 64:383–394

Hamilton, H., Gallagher, P., Ryan, C., Byrne, S., O'Mahony, D. (2011) Potentially Inappropriate Medications defined by STOPP criteria significantly increase the risk of Adverse Drug Events in Older Hospitalized Patients. *Arch Intern Med* 171:1013-19

Keisjers, C.J., van Doorn, A.B., van Kalles, A., de Wildt, D.J., Brouwers, J.R., van de Kamp, H.J. et al. (2014) Structured pharmaceutical analysis of the Structured Tool to Reduce Inappropriate Prescribing is an effective method for final-year medical students to improve polypharmacy skills: a randomized controlled trial. *J Am Geriatr Soc* 62:1353-1359

Leendertse, A.J., van den Bemt, L.A., Poolman, J.B., Stoker, L.J., Egberts, A.C.G., Postma, M.J. (2011) Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. *Value Health* 11:34-40

Lozano-Montoya, I., Vélez-Díaz-Pallarés, M., Abraha, I., Cherubini, A., Soiza, R.L., O'Mahony, D., et al. (2016) Nonpharmacologic Interventions to Prevent Pressure Ulcers in Older Patients: An Overview of Systematic Reviews (The Software ENGINE for the Assessment and optimization of drug and non-drug Therapy in Older persons [SENATOR] Definition of Optimal Evidence-Based Non-drug Therapies in Older People [ONTOP] Series). *J Am Dir Assoc* 17:370e.1-370.e10

Naci, H., Ioannidis, J.P. (2013) Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. *BMJ* 347:f5577

Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., et al. (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. *Psychiatry Res* 41:237-248

O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M.N., Ryan, C., Gallagher, P. (2015) STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing* 44:213-218

Onder, G., Petrovic, M., Tanqiisuran, B., Meinardi, M.C., Markito-Nottenboom, W.P., Somers, A., et al. (2010) Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. *Arch Intern Med* 170:1142-1148  
Permpongkosol, S. (2011) Iatrogenic disease in the elderly: risk factors, consequences and prevention. *Clin Intervent Aging* 6:77-82

Petrovic, M., van der Cammen, T., Onder, G. (2012) Adverse drug reactions in older people: detection and prevention. *Drugs Aging* 29:453-462

Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 cases. *Br Med J* 329:15-19

Rimland, J.M., Abraha, I., Dell'Aquila, G., Cruz-Jentoft, A., Soiza, R., Gudmusson, A., et al. (2016) Effectiveness of Non-pharmacological interventions to prevent falls in older people: a systematic overview. The SENATOR Project ONTOP series. *PLOS ONE* 11:e0161579

Rottenkolber, D., Schmeidl, S., Rotenkolber, M., Farker, K., Salje, K., Mueller, S., et al. (2011) Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. *Pharmacoepidemiol Drug Safety* 20:626-34

Scott, I., Jayathissa, S. (2010) Quality of drug prescribing in older patients: is there a problem and can we improve it? *Intern Med J* 40:7-18

Schiff, G.D., Amato, M.G., Equale, T., Boehne, J.J., Wright, A., Koppel, R., et al. (2015) Computerised physician order-related medication errors: analysis of reported errors and vulnerability testing of current systems. *BMJ Qual Saf* 24:264-271

Vélez-Díaz-Pallarés, M., Lozano-Montoya, I., Abraha, I., Cherubini, A., Soiza, R.L., O'Mahony, D., et al. (2015) Nonpharmacologic Interventions to Heal Pressure Ulcers in Older Patients: An Overview of Systematic Reviews (The SENATOR-ONTOP Series). *J Am Dir Med Assoc* 16:448-469

Vélez-Díaz-Pallarés, M., Lozano-Montoya, I., Correa-Perez, A., Abraha, I., Cherubini, A., Soiza, R.L., et al. (2016) Non-Pharmacological Interventions to Prevent or Treat Pressure Ulcers in Older Patients: Clinical Practice Recommendations. The SENATOR-ONTOP Series. *Eur Geriatr Med* 7:142-148

Table 1: Planned list of conditions that the SENATOR software will advise on Optimal Non-drug Therapy for Older People (ONTOP)

Condition

---

Delirium

Dementia

Falls

Heart failure

Immobility

Orthostatic hypotension

Pressure sores

Stroke

Undernutrition

Urinary incontinence

---